AT1019 injections with focused radiation and PD-1 immunotherapy for advanced solid tumors
Official title: A Phase I Investigator-Initiated Trial (IIT) of AT1019 Combined With Stereotactic Body Radiation Therapy (SBRT) and PD-1 Inhibitor for Advanced Solid Tumors
Run by The Affiliated Hospital of Xuzhou Medical University · NCT07285395 · Data updated 2026-11-12
This will test whether giving injected AT1019 together with focused radiation (SBRT) and a PD‑1 immunotherapy is safe and tolerable for adults with advanced solid tumors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | The Affiliated Hospital of Xuzhou Medical University Academic / other |
| Drugs / interventions | immunotherapy, radiation |
| Locations | 1 site (Xuzhou, Jiangsu) |
| Status | Recruiting |
| Started | November 12, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | December 16, 2025 |
| Trial ID | NCT07285395 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with advanced solid tumors who are receiving PD‑1 immunotherapy, have lesions suitable for SBRT, have at least stable disease on prior immunotherapy, ECOG performance status ≤1, and adequate organ and marrow function are eligible.
✕Probably not a fit
Patients with poor performance status (ECOG >1), significant organ dysfunction, active cardiac conduction/ischemia issues, or tumors not amenable to SBRT are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, investigator-initiated dose-finding trial testing intratumoral AT1019 combined with standard PD‑1 inhibitor treatment and stereotactic body radiation therapy (SBRT). Patients receive PD‑1 inhibitor as scheduled, SBRT in 3–5 weekly fractions of 6–18 Gy, and intratumoral AT1019 injections 1–2 days after each SBRT session. The main goals are to characterize safety, tolerability, and to determine the maximum tolerated dose (MTD) of AT1019 in this combination. Tumor response and safety will be monitored with imaging every six weeks and standard clinical and laboratory assessments.
Why it matters
Potential benefit: If successful, the combination could improve local tumor control and boost immune response to help shrink tumors beyond what PD‑1 therapy or radiation achieve alone.
How similar studies have gone: Combining radiation with PD‑1 inhibitors has shown promising signals in other studies, but intratumoral AT1019 is a novel element with limited prior clinical data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female patients aged ≥ 18 years. 2. Signed the informed consent form and have the psychological capacity to understand it. 3. Patients with advanced solid malignant tumors (such as non-small cell lung cancer, renal cell carcinoma, head and neck cancer, cervical cancer, and urothelial carcinoma) who are receiving immunotherapy and planned to undergo SBRT. Patients are eligible if they achieved at least stable disease during previous immunotherapy. 4. Patients' disease must be evaluated according to RECIST v.1.1. 5. Presence of metastatic lesions amenable to radiation therapy. 6. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1. 7. No evidence of clinically significant conduction abnormalities or active ischemia on electrocardiogram (ECG), as judged by the investigator. 8. Acceptable organ and bone marrow function as demonstrated by the following criteria: (1) Absolute neutrophil count \> 1500 cells/μL; (2) Platelet count \> 50,000 cells/μL; (3) Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); (4) Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 times the ULN; if hepatic metastasis exists, AST/ALT \< 5 times the ULN; (5) Serum creatinine \< 1.5 mg/dL and creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula; (6) Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times the ULN. 9\. Females of childbearing potential (defined as those who have experienced menarche and have not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are not postmenopausal (defined as at least 12 months of amenorrhea with appropriate clinical documentation, such as age \> 45 years)) must undergo a serum pregnancy test prior to the first administration of study treatment and confirm a negative result. 10\. Male and female patients of childbearing potential must agree to use two effective contraceptive methods throughout the study period. Exclusion Criteria: 1. Previous therapeutic radiotherapy to the same lesion. 2. Failure to recover to grade 1 or lower from clinically significant adverse events related to prior anticancer therapy, as judged by the investigator. 3. Previous grade 4 toxicity attributed to immunotherapy. 4. Known untreated brain metastases or treated but unstabilized brain metastases (central nervous system lesions shown on scan to be non-progressive and not requiring corticosteroid use) ≥ 4 weeks prior to enrollment. 5. QT/QTc interval prolongation (QTc interval \> 470 milliseconds). 6. Uncontrolled intercurrent illnesses (including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or psychiatric/social conditions) that, in the investigator's judgment, would limit the patient's compliance with study requirements. 7. Pregnant or lactating women. 8. The Sponsor reserves the right to exclude any patient based on pre-study medical history, physical examination findings, clinical laboratory results, prior medications, or other enrollment criteria.
Where it's running
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Hui Qiu, M.D., Ph.D.
- Email: qiuhui2015@yeah.net
- Phone: +86 0516 83355832
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
AK157D1 injection for advanced solid tumors
A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
MK-2010 alone or with other treatments for advanced solid tumors
This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.
-
Whole-Body Infrared Heating for Advanced Solid Tumors
This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.
-
MK-2010 with Sac-TMT in advanced solid tumors
This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.